The second half of 2026 brings a concentrated sequence of bellwether trials across several of the largest active mass tort dockets in federal court.
For plaintiff firms carrying inventory in social media addiction, NEC baby formula, hair relaxer, and Ozempic litigation, the next six months will produce the jury responses and evidentiary admissions that set valuation benchmarks for the entire plaintiff inventory.
Firms that have not audited their dockets against current scheduling orders are operating without the information this window demands.
MDL 3047: Social media adolescent addiction and the August trial
The most immediate and consequential proceeding is the state attorney general track within MDL 3047. A coalition of 33 state attorneys general is prosecuting Meta, YouTube, Snap, and TikTok for deceptive trade practices and dangerous platform design in People of the State of California, et al. v. Meta Platforms, Inc., Case No. 4:23-cv-05448-YGR. The coalition is explicitly led by Attorneys General Rob Bonta of California, Philip J. Weiser of Colorado, Russell Coleman of Kentucky, and Matthew J. Platkin of New Jersey.
Jury selection commences August 12, 2026, with opening statements proceeding no earlier than August 18 before an eight-member advisory jury. The final joint witness list and frontline trial counsel designations were submitted confidentially to Judge Yvonne Gonzalez Rogers on June 17, 2026, and remain under seal, a standard federal precaution that insulates the immediate trial team from targeted defense opposition research in the final pre-trial window.
The evidentiary foundation driving this trial has been built by the Plaintiffs' Steering Committee, led by Previn Warren of Motley Rice LLC, Khaldoun A. Baghdadi of Walkup, Melodia, Kelly and Schoenberger, and Andre Michel Mura and Michael M. Weinkowitz of Gibbs Mura. Their accelerated discovery pace has forced defendants to produce internal product testing data on a compressed timeline that benefits the entire plaintiff inventory.
The PSC has already secured unsealed internal corporate engineering logs confirming that defendants deployed:
- Infinite scroll architecture designed to eliminate natural stopping points
- Variable-ratio reward schedules that function neurologically like slot machines
- Addiction loops engineered specifically to bypass adolescent psychological defenses
These logs redefine platform algorithms as defectively designed products, dismantling Section 230 publisher immunity arguments that defendants have relied on since the litigation began. When this evidence enters the national record before an advisory jury on August 18, defense leverage across parallel state-level filings will drop. Plaintiff firms that have not secured social media addiction inventory before those admissions go into the record will be acquiring at a disadvantage.
Concurrent bellwether dockets requiring immediate attention
While MDL 3047 commands the most immediate attention, three parallel dockets are reaching procedural milestones that directly affect inventory planning:
- NEC Baby Formula (MDL No. 3026): A second wave of federal bellwether trials in the Northern District of Illinois is scheduled across three trial blocks in August 2026, November 2026, and February 2027. These trials will test jury response to defense epidemiological arguments following early plaintiff-favorable verdicts against Similac and Enfamil manufacturers.
- Hair Relaxer (MDL No. 3060): The court wrapped Daubert hearings on causation theories tying chemical relaxers to uterine and ovarian cancers and has now picked 10 bellwether cases. Trials are expected to begin in 2027. The causation standards set here will define what plaintiffs across the docket must prove.
- Ozempic and Wegovy (MDL No. 3094): Litigation over GLP-1 receptor agonists and serious gastrointestinal injuries, including gastroparesis and ileus, has moved into formal bellwether selection. The cases chosen now will shape early settlement talks and set the causation bar plaintiffs must clear.
Depo-Provera: Immediate audit required
Active trial preparation in Depo-Provera litigation (MDL No. 3140) was put on hold after Pfizer reached a proposed global settlement with plaintiffs' leadership in June 2026. Firms with Depo-Provera inventory should audit client medical records now to meet upcoming settlement matrix requirements. The window between the settlement announcement and the formal registration protocol opening is the operational period that determines which claims receive protected status and how they are prioritized for valuation.
Bard hernia mesh: Venue transfer opposition
Within MDL 2846, plaintiffs Delores Brunson Copeland and Phillip Copeland have filed a formal opposition to transferring their Eastern District of New York action to the Southern District of Ohio. The scheduled hearing on this opposition reflects a broader pattern of plaintiff counsel resisting submission to centralized MDL defense structures post-discovery in favor of litigating in favorable home jurisdictions.
Atraxia Media converts trial intelligence into signed clients
Atraxia Media monitors MDL scheduling orders, bellwether developments, and settlement frameworks across every major active docket. We pair that litigation intelligence with a fully in-house acquisition and intake operation that identifies qualified claimants and delivers signed retainers built to withstand early-stage defense vetting. Contact Atraxia Media to discuss how we can help your firm build inventory positioned for the Q3 and Q4 trial windows.